The abstract is read at the publisher; the summary is JClub's.
Covalent peptide engagers (CPEs) covalently reprogram IgG to target uPAR-expressing tumour cells, enabling robust antibody-dependent cellular phagocytosis.
- Why it matters: Conventional lysine- or cysteine conjugation yields heterogeneous products, and protein engineering is resource-intensive; affinity-guided covalent strategies need better ways to place reactive electrophiles in complex peptide ligands.
- What they did: The authors synthesized CPEs combining an Fc-binding peptide, a SuFEx electrophile, and a target-engager moiety, then assessed covalent labelling kinetics and selectivity by SDS-PAGE and biolayer interferometry (BLI).
- The result: IgG-CPE activity was validated in tumour cell–immune cell co-cultures via antibody-dependent cellular phagocytosis of uPAR-expressing cells, and Herceptin with uPAR-CPE enabled dual-antigen targeting of HER2/uPAR co-expressing cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.